Adage Capital Partners GP L.L.C. Buys Shares of 84,376 Liquidia Co. (NASDAQ:LQDA)

Adage Capital Partners GP L.L.C. purchased a new position in Liquidia Co. (NASDAQ:LQDA) during the 4th quarter, according to its most recent disclosure with the SEC. The fund purchased 84,376 shares of the company’s stock, valued at approximately $992,000.

Several other hedge funds also recently modified their holdings of the business. LM Advisors LLC acquired a new position in Liquidia during the 4th quarter valued at $25,948,000. Invesco Ltd. lifted its stake in shares of Liquidia by 2,675.0% in the fourth quarter. Invesco Ltd. now owns 700,171 shares of the company’s stock valued at $8,234,000 after buying an additional 674,940 shares during the period. Mirabella Financial Services LLP acquired a new stake in Liquidia during the fourth quarter worth about $5,880,000. Eversept Partners LP raised its holdings in Liquidia by 314.1% in the 4th quarter. Eversept Partners LP now owns 571,305 shares of the company’s stock valued at $6,719,000 after acquiring an additional 433,356 shares in the last quarter. Finally, Renaissance Technologies LLC bought a new stake in shares of Liquidia in the 4th quarter worth approximately $2,681,000. 64.54% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

LQDA has been the subject of a number of recent research reports. Scotiabank restated an “outperform” rating on shares of Liquidia in a research note on Thursday, March 20th. HC Wainwright reiterated a “buy” rating and set a $29.00 target price on shares of Liquidia in a research report on Thursday, March 20th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $25.00 price target on shares of Liquidia in a research report on Thursday, April 10th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, Liquidia presently has a consensus rating of “Buy” and a consensus price target of $26.63.

Liquidia Price Performance

Shares of LQDA opened at $13.51 on Wednesday. The business’s 50 day simple moving average is $14.29 and its 200-day simple moving average is $12.94. Liquidia Co. has a one year low of $8.26 and a one year high of $16.81. The company has a market capitalization of $1.15 billion, a P/E ratio of -8.29 and a beta of 0.23.

Liquidia (NASDAQ:LQDA) last announced its earnings results on Wednesday, March 19th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.08). Liquidia had a negative return on equity of 163.21% and a negative net margin of 765.38%. The business had revenue of $2.92 million for the quarter, compared to the consensus estimate of $4.60 million. On average, sell-side analysts anticipate that Liquidia Co. will post -1.51 EPS for the current fiscal year.

Insiders Place Their Bets

In other Liquidia news, CEO Roger Jeffs sold 14,130 shares of the business’s stock in a transaction dated Monday, April 14th. The stock was sold at an average price of $13.57, for a total transaction of $191,744.10. Following the completion of the sale, the chief executive officer now directly owns 1,006,420 shares of the company’s stock, valued at approximately $13,657,119.40. The trade was a 1.38 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, General Counsel Russell Schundler sold 5,964 shares of the firm’s stock in a transaction dated Monday, April 14th. The shares were sold at an average price of $13.57, for a total transaction of $80,931.48. Following the completion of the transaction, the general counsel now directly owns 570,301 shares in the company, valued at $7,738,984.57. This trade represents a 1.03 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 32,683 shares of company stock valued at $443,753. Insiders own 30.10% of the company’s stock.

Liquidia Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).